Literature DB >> 25132240

Single fraction radiosurgery for the treatment of renal tumors.

Michael Staehler1, Markus Bader2, Boris Schlenker2, Jozefina Casuscelli2, Alexander Karl2, Alexander Roosen2, Christian G Stief2, Axel Bex3, Berndt Wowra4, Alexander Muacevic4.   

Abstract

PURPOSE: High dose local stereotactic radiosurgery was performed in select patients to improve local tumor control and overall survival. We report on patients with renal tumors treated with single fraction robotic stereotactic radiosurgery.
MATERIALS AND METHODS: A total of 40 patients with a median age of 64 years who had an indication for nephrectomy and subsequent hemodialysis were entered in a prospective case-control study of single fraction stereotactic radiosurgery. Of the patients 11 had transitional cell cancer and 29 had renal cell cancer. Tumor response, renal function, survival and adverse events were estimated every 3 months. Followup was at least 6 months.
RESULTS: A total of 45 renal tumors were treated. Median followup was 28.1 months (range 6.0 to 78.3). The local tumor control rate 9 months after stereotactic radiosurgery was 98% (95% CI 89-99). There was a measurable size reduction in 38 lesions, including complete remission in 19. Renal function remained stable. Using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation median creatinine clearance was 76.8 (range 25.3 to 126.3) and 70.3 ml/minute/1.73 m(2) (range 18.6 to 127.3) at baseline and followup, respectively (p = 0.89). Grade I erythrodermia developed in 1 patient, 3 reported grade I fatigue and 2 reported grade I nausea. Nephrectomy was avoided in all cases.
CONCLUSIONS: Single fraction stereotactic radiosurgery as an outpatient procedure is a treatment modality with short-term safety and efficacy. It avoids treatment related loss of renal function and hemodialysis in select patients with transitional or renal cell cancer. At short followup oncologic results were similar to those of other ablative techniques for renal tumors. To date functional results have been excellent. Further studies are needed to determine the long-term results and limits of stereotactic radiosurgery in this setting.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma; kidney; radiosurgery; renal cell; robotics; transitional cell

Mesh:

Year:  2014        PMID: 25132240     DOI: 10.1016/j.juro.2014.08.044

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

Review 1.  Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.

Authors:  Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo
Journal:  Nat Rev Urol       Date:  2017-06-20       Impact factor: 14.432

Review 2.  Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions.

Authors:  Anand Swaminath; William Chu
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

3.  Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery.

Authors:  Chang W Song; Yoon-Jin Lee; Robert J Griffin; Inhwan Park; Nathan A Koonce; Susanta Hui; Mi-Sook Kim; Kathryn E Dusenbery; Paul W Sperduto; L Chinsoo Cho
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-16       Impact factor: 7.038

Review 4.  Renal Function Following Nephron Sparing Procedures: Simply a Matter of Volume?

Authors:  Michael J Biles; G Joel DeCastro; Solomon L Woldu
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

5.  Stereotactic body radiation therapy for oligometastatic renal cell carcinoma: improving outcomes in an otherwise radioresistant malignancy.

Authors:  Thomas H Beckham; Brandon S Imber; Charles B Simone
Journal:  Ann Transl Med       Date:  2019-07

6.  Prospective evaluation of CT-guided HDR brachytherapy as a local ablative treatment for renal masses: a single-arm pilot trial.

Authors:  R Damm; T Streitparth; P Hass; M Seidensticker; C Heinze; M Powerski; J J Wendler; U B Liehr; K Mohnike; M Pech; J Ricke
Journal:  Strahlenther Onkol       Date:  2019-07-25       Impact factor: 3.621

Review 7.  Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Cédric Panje; Nikolaus Andratschke; Thomas B Brunner; Maximilian Niyazi; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2016-10-24       Impact factor: 3.621

Review 8.  Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery.

Authors:  Mi-Sook Kim; Wonwoo Kim; In Hwan Park; Hee Jong Kim; Eunjin Lee; Jae-Hoon Jung; Lawrence Chinsoo Cho; Chang W Song
Journal:  Radiat Oncol J       Date:  2015-12-30

9.  Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.

Authors:  Takaya Yamamoto; Noriyuki Kadoya; Ken Takeda; Haruo Matsushita; Rei Umezawa; Kiyokazu Sato; Masaki Kubozono; Kengo Ito; Yojiro Ishikawa; Maiko Kozumi; Noriyoshi Takahashi; Yu Katagiri; Hiroshi Onishi; Keiichi Jingu
Journal:  Radiat Oncol       Date:  2016-05-26       Impact factor: 3.481

Review 10.  Stereotactic Ablative Radiotherapy for the Treatment of Clinically Localized Renal Cell Carcinoma.

Authors:  Scott P Campbell; Daniel Y Song; Phillip M Pierorazio; Mohamad E Allaf; Michael A Gorin
Journal:  J Oncol       Date:  2015-11-11       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.